Stuart A. Ross, MB CHB, FRACP, FRCP(C) 

Slides:



Advertisements
Similar presentations
Low-Dose Aspirin in Patients with Stable Cardiovascular Disease: A Meta-analysis Jeffrey S. Berger, MD, MS, David L. Brown, MD, Richard C. Becker, MD The.
Advertisements

Copyright © 2015 by the American Osteopathic Association.
Copyright © 2015 by the American Osteopathic Association.
James Thrasher, MD  The American Journal of Medicine 
Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes  Bernt Johan von Scholten, Tine.
Copyright © 2015 by the American Osteopathic Association.
From: Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 DiabetesA Systematic Review and Meta-analysis Ann Intern Med.
Recognition and First-Line Treatment of Anaphylaxis
Anne B. Yates, MD  The American Journal of Medicine 
Paul D. Stein, MD, Fadi Matta, MD, Mary J. Hughes, DO 
Matthew P. Gilbert, DO, MPH, Richard E. Pratley, MD 
Bleeding Toes in Diabetic Neuropathy
Dipeptidyl Peptidase-4 Inhibitors, Peripheral Arterial Disease, and Lower Extremity Amputation Risk in Diabetic Patients  Chun-Chin Chang, MD, Yung-Tai.
Luigi F. Meneghini, MD, MBA  The American Journal of Medicine 
An Unusual Cause of Leg Ulcerations
Richard V. Milani, MD, Carl J. Lavie, MD, Robert M
Bleeding Toes in Diabetic Neuropathy
James H. Liu, MD  The American Journal of Medicine 
Antihyperglycemic therapy in type 2 diabetes: general recommendations.
Choosing glucose-lowering medication in those with established ASCVD, HF, and CKD. CV, cardiovascular; DPP-4i, dipeptidyl peptidase 4 inhibitor; GLP-1.
Clinical Application of Incretin-Based Therapy: Therapeutic Potential, Patient Selection and Clinical Use  David M. Kendall, MD, Robert M. Cuddihy, MD,
Bertha Wong, MD, Muhammad M. Mamdani, PharmD, MPH, Catherine H
Safety and Efficacy of Incretin-Based Therapies in Patients With Type 2 Diabetes Mellitus and CKD: A Systematic Review and Meta-analysis  Patricia M.
Matthew I. Worthley, MBBS, PhD, FRACP, Fiona M
Options for Combination Therapy in Type 2 Diabetes: Comparison of the ADA/EASD Position Statement and AACE/ACE Algorithm  Timothy Bailey, MD  The American.
James Thrasher, MD  The American Journal of Medicine 
Systematic Review and Meta-analysis of Adverse Events of Low-dose Aspirin and Clopidogrel in Randomized Controlled Trials  Kenneth R. McQuaid, MD, Loren.
Athena Philis-Tsimikas, MD  The American Journal of Medicine 
Fainting with HIV The American Journal of Medicine
Schizophrenia for Primary Care Providers: How to Contribute to the Care of a Vulnerable Patient Population  Mark Viron, MD, Travis Baggett, MD, MPH, Michele.
Epidemiology of Myelodysplastic Syndromes
Antihyperglycemic therapy in type 2 diabetes: general recommendations (17). Antihyperglycemic therapy in type 2 diabetes: general recommendations (17).
The Impact of the Host on Fungal Infections
Robert Goulden, MBBS, MSc, MPhil, MA  The American Journal of Medicine 
Dipeptidyl Peptidase-4 Inhibitors, Peripheral Arterial Disease, and Lower Extremity Amputation Risk in Diabetic Patients  Chun-Chin Chang, MD, Yung-Tai.
Antihyperglycemic therapy in type 2 diabetes: general recommendations.
Michael A. Pfaller, MD  The American Journal of Medicine 
Individualizing Insulin Therapy in the Management of Type 2 Diabetes
The Reply The American Journal of Medicine
Matthew P. Gilbert, DO, MPH, Richard E. Pratley, MD 
TIA for the Internist The American Journal of Medicine
Gout in African Americans
Treatment of hepatitis C
Predicted and observed HbA1c levels using doubly robust estimation adjusting for either a comprehensive set of confounders (left panel) or a set of confounders.
Use of Serum c-Peptide Level to Simplify Diabetes Treatment Regimens in Older Adults  Medha N. Munshi, MD, Mellody Hayes, BA, Adrianne Sternthal, Darlene.
A New Drug Target for Type 2 Diabetes
Resistant Hypertension and the Pivotal Role for Mineralocorticoid Receptor Antagonists: A Clinical Update 2016  Murray Epstein, MD, Daniel A. Duprez,
Changes in A1C (A), body weight (B), and systolic blood pressure (C) with canagliflozin in combination with incretin-based therapies. *In the dose-advancement.
Trends in the relative contribution of each second-line diabetes medication class, by quarter, as a percent of all second-line prescribing, 2011–2015.
Predicted and observed BMI levels using doubly robust estimation adjusting for either a comprehensive set of confounders (left panel) or a set of confounders.
Opioid Use, Misuse, and Abuse in Patients Labeled as Fibromyalgia
Insomnia in the Elderly: Cause, Approach, and Treatment
Age Differences in Treatment and Control of Hypertension in US Physician Offices, : A Serial Cross-sectional Study  Anna Gu, MD, PhD, Yu Yue,
Purple Urinary Bag Syndrome
A Post-cure Complication
Glycaemic management of type 2 diabetes
Barriers to Adult Immunization
Trial Quality in Nephrology: How Are We Measuring Up?
Glucose-lowering medication in type 2 diabetes: overall approach.
Direct Observation of Residents: A Model for an Assessment System
Falls in Older Adults: Risk Assessment, Management and Prevention
ADA type 2 diabetes glycemic control algorithm, reproduced with permission from ref. 4. *Usually a basal insulin (neutral protamine Hagedorn, glargine,
Invasive Mycoses: Diagnostic Challenges
Matthew W. Martinez, MD, Keith G. Rasmussen, MD, Paul S
Longer Lengths of Stay and Higher Risk of Mortality among Inpatients of Physicians with More Years in Practice  William N. Southern, MD, MS, Eran Y. Bellin,
Toward a More Responsible News Media
Comment on “Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case-control.
Incretin Therapies: Effects Beyond Glycemic Control
Glucose-lowering medication in type 2 diabetes: overall approach.
Fig. 1. Antihyperglycemic therapy algorithm for adult patients with type 2 diabetes mellitus (T2DM). The algorithm stratifies the choice of medications.
Presentation transcript:

Breaking Down Patient and Physician Barriers to Optimize Glycemic Control in Type 2 Diabetes  Stuart A. Ross, MB CHB, FRACP, FRCP(C)  The American Journal of Medicine  Volume 126, Issue 9, Pages S38-S48 (September 2013) DOI: 10.1016/j.amjmed.2013.06.012 Copyright © 2013 Elsevier Inc. Terms and Conditions

Figure 1 Factors influencing treatment success (adapted from Allen et al, 200912). The American Journal of Medicine 2013 126, S38-S48DOI: (10.1016/j.amjmed.2013.06.012) Copyright © 2013 Elsevier Inc. Terms and Conditions

Figure 2 Weighted mean weight change (95% confidence interval) observed with various noninsulin type 2 diabetes therapies (data from Phung et al, 201040). αGIs = alpha-glucosidase inhibitors; DPP-4is = dipeptidyl peptidase-4 inhibitors; GLP-1RA = glucagon-like peptide-1 receptor agonist; SU = sulfonylurea; TZD = thiazolidinedione. The American Journal of Medicine 2013 126, S38-S48DOI: (10.1016/j.amjmed.2013.06.012) Copyright © 2013 Elsevier Inc. Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.